Paper Details

  1. Home
  2. Paper Details

Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin.

Author: FittsD, GrallaR J, GrunbergS M, KaplanH G, NavariR M, PalmerR

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Granisetron was effective in controlling vomiting in 57% to 60% of patients receiving cisplatin. The 10, 20, and 40 micrograms/kg doses were equally effective and well tolerated.
Paper Details　
Original Abstract of the Article :
PURPOSE: To assess the antiemetic effects and safety profile of four different doses of granisetron (Kytril; SmithKline Beecham Pharmaceuticals, Philadelphia, PA) when administered as a single intravenous (IV) dose for prophylaxis of cisplatin-induced nausea and vomiting. PATIENTS AND METHODS: One ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1200/JCO.1994.12.10.2204

データ提供：米国国立医学図書館（NLM）

Granisetron: A New Oasis in the Desert of Chemotherapy-Induced Nausea

Chemotherapy, a vital weapon in the fight against cancer, can often come with unpleasant side effects, including nausea and vomiting. This research examines the efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, as a preventative measure against cisplatin-induced nausea and vomiting. The study investigated the effectiveness of different doses of granisetron administered intravenously to patients receiving high-dose cisplatin.

A Ray of Hope in the Desert of Nausea

The study demonstrated that granisetron, administered as a single intravenous dose, effectively reduced nausea and vomiting in patients receiving high-dose cisplatin. The results showed a significant reduction in the incidence of vomiting and retching, with a dose-dependent response.

Navigating the Desert of Chemotherapy Side Effects: Finding Relief

This research highlights the potential of granisetron for managing the debilitating side effects of chemotherapy. By reducing nausea and vomiting, granisetron can significantly improve the quality of life for cancer patients undergoing treatment.

Dr. Camel's Conclusion

The journey through chemotherapy can be a harsh desert, often accompanied by waves of nausea and vomiting. This research offers a potential oasis, highlighting the benefits of granisetron in managing these challenging side effects. As we continue to explore new approaches to improving the lives of cancer patients, it’s important to embrace innovations like granisetron, bringing us closer to a more comfortable and manageable treatment experience.

Date :
  1. Date Completed 1994-11-04
  2. Date Revised 2017-02-10
Further Info :

Pubmed ID

7931490

DOI: Digital Object Identifier

10.1200/JCO.1994.12.10.2204

Related Literature

Article Analysis
・Effects of granisetron
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.